FDA: No Excess Mortality Risk From Paclitaxel PAD DevicesHealth care

Caring patient and health is our expertise.|The US Food and Drug Administration (FDA) has determined that paclitaxel-delivering stents and balloons for peripheral-artery interventions do not pose an excess mortality risk, the agency said today in a statement to healthcare providers.

Medscape

FDA: No Excess Mortality Risk From Paclitaxel PAD Devices

FDA: No Excess Mortality Risk From Paclitaxel PAD Devices

The US Food and Drug Administration (FDA) has determined that paclitaxel-delivering stents and balloons for peripheral-artery interventions do not pose an excess mortality risk, the agency said today in a statement to healthcare providers.